CONFERENCE UPDATE: ACC 2022

No additional reduction in leaflet thrombosis and cerebral thromboembolism with edoxaban over DAPT after TAVR

CARDIOLOGY
30 Jun 2022

References
  1. Duk-Woo Park et al. Edoxaban Versus Dual Antiplatelet Therapy for Valve Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial. Presented at American College of Cardiology Meeting 2022; April 2-4, 2022.
LEAFLET THROMBOSIS
TRANSCATHETER AORTIC-VALVE REPLACEMENT
CEREBRAL THROMBOEMBOLISM
CEREBRAL EMBOLISM
ORAL ANTICOAGULANTS
EDOXABAN
DUAL ANTIPLATELET THERAPY
CEREBRAL LESIONS
NEUROLOGIC DYSFUNCTION
NEUROCOGNITIVE DYSFUNCTION
ADAPT-TAVR
Related Articles

Ticagrelor alone after drug-eluting coronary stenting halves major bleeding risks in PCI patients regardless of ACS status

STUDY DESIGN  The 2023 ESC guidelines advocate for a standard treatment of 12-month dual antiplatelet therapy (DAPT) in patients with acute coronary syndrome (ACS) as a Class I recommendation with a high level of evidence.1 For those who may benefit from shorter DAPT regimens depending on their spe
CARDIOLOGY
03 Dec 2024